Hana I. Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hana I. Lim has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Katherine A. Hajjar
Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York
2 shared publications Danielle Brandman
Department of Medicine Division of Gastroenterology and Hepatology Weill Cornell Medical College New York New York USA
1 shared publication- Dena Almeida
Microscopy and Image Analysis Core, Weill Cornell Medical College, Cornell University 5 , New York City, NY
1 shared publication Elora Basu
1 shared publication- Frances Mae West
Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA; Department of Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
1 shared publication Gustavo H. B. Maegawa
Department of Pediatrics, Metabolism and Genetics Vagelos College of Physicians and Surgeons Columbia University Medical Center New York New York USA
1 shared publication
Latest Publications
- Open Access
- 19 March 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2)
Sepsis-triggered proteolysis of profibrinolytic annexin A2 associated with microvasculopathy-related organ dysfunction
- 19 March 2026
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 3 (2)
Open AccessSepsis-triggered proteolysis of profibrinolytic annexin A2 associated with microvasculopathy-related organ dysfunction
- 1 September 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (9) , 2461-2471
Management of Stroke in Patients With Chronic Liver Disease: A Practical Review
Chronic liver disease (CLD) is a highly prevalent condition. There is burgeoning recognition that there are many people with subclinical liver disease that may nonetheless be clinically significant. CLD has a variety of systemic aberrations relevant to stroke, including thrombocytopenia, coagulopathy, elevated liver enzymes, and altered drug metabolism. There is a growing body of literature on the intersection of CLD and stroke. Despite this, there have been few efforts to synthesize these data, and stroke guidelines provide scant guidance on this topic. To fill this gap, this multidisciplinary review provides a contemporary overview of CLD for the vascular neurologist while appraising data regarding the impact of CLD on stroke risk, mechanisms, and outcomes. Finally, the review addresses acute and chronic treatment considerations for patients with stroke—ischemic and hemorrhagic—and CLD.
- 1 September 2023
- Published by Wolters Kluwer Health in Stroke
- Vol. 54 (9) , 2461-2471
Management of Stroke in Patients With Chronic Liver Disease: A Practical Review
Chronic liver disease (CLD) is a highly prevalent condition. There is burgeoning recognition that there are many people with subclinical liver disease that may nonetheless be clinically significant. CLD has a variety of systemic aberrations relevant to stroke, including thrombocytopenia, coagulopathy, elevated liver enzymes, and altered drug metabolism. There is a growing body of literature on the intersection of CLD and stroke. Despite this, there have been few efforts to synthesize these data, and stroke guidelines provide scant guidance on this topic. To fill this gap, this multidisciplinary review provides a contemporary overview of CLD for the vascular neurologist while appraising data regarding the impact of CLD on stroke risk, mechanisms, and outcomes. Finally, the review addresses acute and chronic treatment considerations for patients with stroke—ischemic and hemorrhagic—and CLD.
- Open Access
- 25 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6836
Annexin A2 in Fibrinolysis, Inflammation and Fibrosis
As a cell surface tissue plasminogen activator (tPA)-plasminogen receptor, the annexin A2 (A2) complex facilitates plasmin generation on the endothelial cell surface, and is an established regulator of hemostasis. Whereas A2 is overexpressed in hemorrhagic disease such as acute promyelocytic leukemia, its underexpression or impairment may result in thrombosis, as in antiphospholipid syndrome, venous thromboembolism, or atherosclerosis. Within immune response cells, A2 orchestrates membrane repair, vesicle fusion, and cytoskeletal organization, thus playing a critical role in inflammatory response and tissue injury. Dysregulation of A2 is evident in multiple human disorders, and may contribute to the pathogenesis of various inflammatory disorders. The fibrinolytic system, moreover, is central to wound healing through its ability to remodel the provisional matrix and promote angiogenesis. A2 dysfunction may also promote tissue fibrogenesis and end-organ fibrosis.
- 25 June 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (13) , 6836
Open AccessAnnexin A2 in Fibrinolysis, Inflammation and Fibrosis
As a cell surface tissue plasminogen activator (tPA)-plasminogen receptor, the annexin A2 (A2) complex facilitates plasmin generation on the endothelial cell surface, and is an established regulator of hemostasis. Whereas A2 is overexpressed in hemorrhagic disease such as acute promyelocytic leukemia, its underexpression or impairment may result in thrombosis, as in antiphospholipid syndrome, venous thromboembolism, or atherosclerosis. Within immune response cells, A2 orchestrates membrane repair, vesicle fusion, and cytoskeletal organization, thus playing a critical role in inflammatory response and tissue injury. Dysregulation of A2 is evident in multiple human disorders, and may contribute to the pathogenesis of various inflammatory disorders. The fibrinolytic system, moreover, is central to wound healing through its ability to remodel the provisional matrix and promote angiogenesis. A2 dysfunction may also promote tissue fibrogenesis and end-organ fibrosis.